Effects of exposure to environmental mycobacteria on immunity conferred by bacille calmette-guerin (BCG) vaccine by HO PEIYING
 
 
EFFECTS OF EXPOSURE TO ENVIRONMENTAL 
MYCOBACTERIA ON IMMUNITY CONFERRED BY  















A THESIS SUBMITTED 
 
 
FOR THE DEGREE OF MASTER OF SCIENCE 
 
 
DEPARTMENT OF MICROBIOLOGY 
 
 









  iii   
ACKNOWLEDGEMENTS 
 
I would like to give my most heartfelt gratitude to my supervisor, Dr Seah Geok Teng, 
for her precious time, tireless guidance and invaluable advice for my project. In addition, 
my sincere thanks also goes out to the following people, who have helped me in one way 
or another, without whom I would not have been able to successfully complete this 
project. My special thanks to Mrs Thong Khar Tiang for helping me with purchasing 
matters and for running the flow cytometer, as well as Mr Joseph Thong for his advice on 
animal housing matters. I would also like to convey my warmest appreciation to my 
colleagues, Carmen, Chai Lian, Irene, Jen Yan, Joanne, Wendy, Wei Xing and Wei Ling, 
for their support and suggestions for my experiments. Sincere thanks goes out especially 
to Irene, Wendy and Wei Xing for their tireless help during my period of research in the 
lab. Lastly, I give my wholehearted thanks to my family for their support, especially 
Aaron for his words of advice and encouragement. 
  iii   
TABLE OF CONTENTS  
SUMMARY ................................................................................................................. v 
LIST OF TABLES .......................................................................................................... vii 
LIST OF FIGURES ....................................................................................................... viii 
ABBREVIATIONS.......................................................................................................... ix 
CHAPTER 1   LITERATURE REVIEW ................................................................... 1 
1.1  Tuberculosis situation in the world..................................................................... 1 
1.2 Mycobacterim tuberculosis – an intracellular pathogen ..................................... 1 
1.3 Immune responses to TB .................................................................................... 2 
1.3.1 T helper cells................................................................................................... 2 
1.3.2 Cytotoxicity in response to M. tuberculosis ................................................... 3 
1.3.2.1  Natural killer (NK) cells ........................................................................ 3 
1.3.2.2  CD4+ cytolytic T cells............................................................................ 4 
1.3.2.3  CD8+ T cells........................................................................................... 4 
1.3.2.4   γδ T cells ............................................................................................... 5 
1.4 Regulatory T cells (Treg).................................................................................... 5 
1.5 Roles of cytokines in M. tuberculosis infection.................................................. 6 
1.5.1 Interferon γ (IFN-γ)......................................................................................... 6 
1.5.2 Interleukin 4 (IL-4) ......................................................................................... 7 
1.5.3 Transforming growth factor β (TGF-β) .......................................................... 8 
1.5.4 Interleukin 10 (IL-10) ..................................................................................... 9 
1.6 BCG as a vaccine ................................................................................................ 9 
1.7 Environmental mycobacteria (Env) .................................................................. 10 




1.8 Effect of environmental mycobacteria (Env) exposure on subsequent BCG 
vaccination .................................................................................................................... 11 
CHAPTER 2   AIMS AND OBJECTIVES .............................................................. 14 
CHAPTER 3  MATERIALS AND METHODS ...................................................... 16 
3.1 Mice .................................................................................................................. 16 
3.2 Bacteria ............................................................................................................. 16 
3.3 Preparation of heat-killed and live mycobacterial cultures............................... 17 
3.4 Murine immunisation and live BCG challenge ................................................ 17 
3.5 Trypan Blue exclusion assay ............................................................................ 18 
3.6 Isolation of murine peritoneal macrophages..................................................... 18 
3.7 Isolation of murine splenocytes and lung tissue ............................................... 19 
3.8 Positive cell selection using magnetic beads .................................................... 19 
3.9 Bronchoalveolar lavage (BAL)......................................................................... 20 
3.10 Cytokine analysis by ELISA........................................................................... 221 
3.11 BCG killing assay by peritoneal macrophages ............................................... 221 
3.12 Flow Cytometry ................................................................................................ 22 
3.12.1 Cell surface markers ................................................................................. 22 
3.12.2 Intracellular cytokine and perforin staining.............................................. 23 
3.13 Cytotoxicity assay............................................................................................. 24 
3.13.1 Principle of assay ...................................................................................... 24 
3.13.2 Cytotoxicity assay experimental set-up .................................................... 25 
3.14 Statistical analysis............................................................................................. 26 
CHAPTER 4   RESULTS ........................................................................................... 27 
  iii  
4.1 Distribution of inflammatory cells in lungs of BCG-infected mice ................. 27 
4.2       Cytokine expression in different cell subsets in BCG-infected lungs .............. 37 
4.3 Distribution of CD4+ and CD4- cells in the spleen ........................................... 39 
4.4 Cytotoxic activity following BCG challenge.................................................... 40 
4.5 Cytotoxic activity in M. chelonae-sensitised mice ........................................... 43 
4.6 Perforin expression in BCG-infected lungs ...................................................... 43 
4.7 Macrophage mycobactericidal activity ............................................................. 43 
4.8 Cytokine production following M. chelonae sensitisation ............................... 47 
4.8.1 IL-10 production ............................................................................................... 47 
4.8.2 IL-4 and TGF-β production .............................................................................. 49 
4.8.3 IL-2 production ................................................................................................. 50 
4.8.4 IFN- γ production.............................................................................................. 52 
CHAPTER 5   DISCUSSION ..................................................................................... 55 
5.1 Cytolytic activity of different cell subsets ........................................................ 55 
5.2 Cytotoxic CD4+ T cells ..................................................................................... 57 
5.3 Cytotoxicity is higher at later time-points after BCG infection........................ 59 
5.4 Possible induction of regulatory T cells by M. chelonae sensitisation ............. 60 
5.5 Role of IFN-γ in cytotoxic responses................................................................ 62 
5.6 Effects of Env sensitisation on BCG-induced immunity.................................. 63 
5.7 Conclusion ........................................................................................................ 66 
REFERENCES ............................................................................................................... 67 
APPENDICES ............................................................................................................... 76 
  iv  
Summary 
 
Epidemiological evidence suggests that the efficacy of Mycobacterium bovis bacille 
Calmette-Guérin (BCG), as a tuberculosis (TB) vaccine in human populations, is 
influenced by prior sensitisation to environmental mycobacteria (Env). After priming 
with certain Env species and subsequent vaccination with BCG, murine hosts show 
reduced proliferation of BCG in vivo. This may be because memory responses to Env 
antigens are cross-reactive with antigens of other mycobacterium species. However, the 
immunological mechanisms underlying these effects remain unknown. This project 
aimed to uncover these mechanisms using a murine model of Mycobacterium chelonae 
sensitisation followed by intranasal BCG infection. Cytotoxic responses of splenocytes 
against autologous BCG-infected macrophages of mice sensitised with M. chelonae (a 
representation of Env), with or without subsequent intranasal BCG infection, were 
measured by a non-radioactive cytotoxicity assay. Splenocytes were sorted into CD4 and 
non-CD4 subsets to investigate the T cell subsets involved in these cytotoxic responses. 
The levels of relevant cytokines produced by splenic CD4+ and CD4- T cells were 
determined by ELISA. Env sensitisation increased cytotoxicity of splenic T cells against 
autologous BCG-infected macrophages, both before and after BCG challenge. This was 
especially noted at 3 weeks post-infection in the CD4+ fraction, which also contributed 
largely to the perforin production in those mice. However, the cytotoxicity was not 
directly correlated with IFN-γ production. Cytokine production and inflammatory cell 
count, at the site of infection (i.e. lung) was also determined, by flow cytometry. Reduced 
percentages of all inflammatory cells in the lungs of sensitised mice in response to 
  iv  v 
intranasal BCG, and a higher proportion of IL-10 producing cells in the lung tissue, 
relative to control mice, suggest induction of regulatory T cells following Env 
sensitisation. Thus, CD4+ mediated cytotoxicity in Env-primed mice against BCG-
infected cells is a mechanism behind the effect of Env exposure on subsequent BCG 
vaccination. The results of this work have an impact on the use of BCG as a vaccine as 
well as development of future vaccines against TB, given that many candidate TB 
vaccines on clinical trials currently involve BCG in prime-boost strategies or genetically-
modified BCG as a vector to carry novel antigens. 
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CHAPTER 1   LITERATURE REVIEW 
 
1.1  Tuberculosis situation in the world 
Tuberculosis (TB) is amongst the global leading causes of death by a single infectious 
pathogen. Human disease is mainly caused by members of the Mycobacterium 
tuberculosis (Mtb) complex, comprising of Mtb, M. bovis, M. africanum M. canettii and 
M. microti (Cosma, 2003). The World Health Organization (WHO) has declared TB a 
‘global emergency’, and estimates that two million people die from this curable disease 
annually. TB can be treated with a cocktail of antibiotics but this requires at least six 
months, with potential toxicity and cost issues. Due to poor availability or compliance to 
drug treatment, especially in poor developing areas, direct observed therapy (DOTS) is 
advocated but is difficult to administer. With the rising trend in HIV (human 
immunodeficiency virus) infections as well as the appearance of multiple-drug resistant 
(MDR) strains of Mtb, the TB situation worldwide is worsening, with almost nine million 
new cases in 2004 (WHO, 2006). 
 
 
1.2 Mycobacterim tuberculosis – an intracellular pathogen 
Tubercle bacilli are intracellular pathogens, surviving within lung macrophages after the 
human host inhales airborne droplets containing the bacteria.  Alveolar macrophages, 
which are believed to be the principal host cells of the bacteria, play dual roles in the 
lifestyle of Mtb – as a first line of cellular defence, as well as a site for bacterial survival 
and replication. The bacteria can escape the host immune system by interfering with 
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membrane trafficking and avoiding phagolysosomal fusion. Nonetheless, in infected 
individuals, dendritic cells (DCs) and macrophages recruited to the lung take up the 
bacteria, migrate to the draining lymph nodes and initiate T-helper 1 (Th1) responses by 
presenting Mtb antigens to T cells. Eventually, granulomas form in response to persistent 
intracellular Mtb. In these structures, macrophages, DCs, T cells and B cells surround 
single infected macrophages (Cosma, 2003). Any remaining Mtb can persist in a latent 
state in the host and reactivation of such bacteria leads to active disease. There is some 
evidence that latent mycobacteria survive under conditions of nutrient deprivation and 
hypoxia within granulomas by reducing their metabolic activity and persisting in a non-
dividing or slowly dividing state (Raja 2004).  
 
1.3 Immune responses to TB 
Protective immune responses against all mycobacteria depends on cell-mediated 
immunity provided by T cells. The intracellular lifestyle of Mtb makes T cell effector 
functions more important than antibodies in controlling or eliminating Mtb infections. 
Two major effector functions are the T helper and cytotoxic activities, which shall be 
further described below. 
 
1.3.1 T helper cells 
CD4+ T cells are the most important subset of T cells for controlling Mtb infections. This 
is clearly seen in numerous murine studies as well as in HIV-infected individuals, who 
have a significantly lowered CD4+ T cell count and are markedly more susceptible to TB 
(Flynn and Chan 2001; Elkins, 2003). The full range of effector mechanisms utilised by 
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CD4+ T cells in combating TB remains to be elucidated. However, the production of IFN-
γ in activating macrophages to release reactive oxygen and nitrogen intermediates is 
generally recognised as a key effector mechanism of CD4+ cells in murine models of TB 
(Flynn and Chan 2001). 
 
1.3.2 Cytotoxicity in response to M. tuberculosis  
Cytotoxic T lymphocytes (CTLs) have increasingly been reported in TB patients, and are 
likely to have major roles in anti-TB immunity (Lewinsohn, 1998). Potential cytolytic 
cell subsets involved in lysis of Mtb-infected macrophages are CD4+, CD8+ and γδ T 
cells, as well as natural killer (NK) cells. 
 
1.3.2.1  Natural killer (NK) cells 
NK cells are cytolytic effector cells of innate immunity, and have been shown to be 
involved in immune responses against TB. Human NK cells have been demonstrated to 
respond to live Mtb in vitro and increased NK activity is observed in active pulmonary 
TB patients (Yoneda, 1983; Esin, 1996). The expansion of NK cells after Mycobacterium 
bovis bacille Calmette- Guérin (BCG), or Mtb infection in mice has also been reported, 
suggesting a role for NK cells in immune responses against TB (Falcone, 1993; 
Junqueira-Kipnis, 2003). The direct role of NK cells in mycobacteria infections, 
however, is not well understood. 
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1.3.2.2  CD4+ cytolytic T cells 
Apart from being involved in T helper responses, CD4+ T cells can also exhibit 
cytotoxicity. Upregulation of mRNA for granulysin, perforin and granzymes A and B, is 
observed in human CD4+ T cells after in vitro stimulation with Mtb, indicating a cytolytic 
role of these cells against TB (Canaday, 2001). Furthermore, CD4+ cells from peripheral 
blood of patients with active TB have been reported to display cytotoxic responses 
against autologous Mtb-pulsed macrophages, and this cytotoxicity diminishes with 
severity of TB. However, it is unclear whether the opposite, where patients with less 
severe TB have better cytotoxic responses, holds true (De La Barrera, 2003). The same 
study shows that the CD4-mediated cytotoxicity occurs via the Fas/ Fas-ligand 
mechanism. However, other studies on CD4+ T cell clones have reported perforin-
dependent mechanisms for their cytolytic activity (Susskind, 1996; Kaneko 2000). 
 
1.3.2.3  CD8+ T cells 
The most widely reported cell type exhibiting cytotoxicity in TB studies is the CD8+ cell 
(Sousa, 2000; van Pinxteren, 2000). There is evidence for exocytosis of granule contents 
as the mechanism behind CD8+ CTLs in TB. Human CD8+ T cells exert cytotoxicity on 
Mtb-infected macrophages via a granule (perforin/ granzyme or granulysin)-dependent 
mechanism that is independent of Fas/ Fas-ligand interaction (Stenger, 1997; Stenger, 
1998). The perforin/ granzmye pathway is also suggested to be more important than the 
Fas/ Fas-ligand pathway in lysis of Mtb-infected macrophages by CD8+ CTLs in mice 
(Silva and Lowrie 2000). Another study showed that although granule exocytosis is 
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required for the cytotoxic activity of human CD8+ T cells, perforin inhibition did not 
affect restriction of Mtb growth (Canaday, 2001). 
 
1.3.2.4   γδ T cells 
γδ T cells are readily activated by Mtb and secrete antigen-specific IFN-γ (Ladel, 1995a). 
Murine studies with T cell receptor (TCR) δ gene deletion mutants show that γδ T cells 
play a major role in protective responses against TB, as these mice died after Mtb 
infection, while immunocompetent control mice survived (Ladel, 1995b). Futhermore, γδ 
T cell-mediated lytic activity is observed in ex vivo effector cells from TB patients (De 
La Barrera, 2003). 
 
1.4 Regulatory T cells (Treg) 
Regulatory T cells (Treg) exert suppressive effects on immune responses, and therefore 
are an important consideration when evaluating efficacy of immunity against infectious 
pathogens. Two Treg populations have been described, but not in infectious disease 
models – IL-10 secreting and naturally occurring Treg cells (O'Garra, 2004). Naturally 
occurring Tregs are a subset of CD4+ T cells that are able to suppress the effector 
functions of CD4+ and CD8+ T cells (Thornton and Shevach 1998; Murakami, 2002). 
These are of the CD4+CD25+ phenotype, and the transcription factor FoxP3 is known as a 
specific molecular marker for such cells (Fontenot, 2003; Fontenot and Rudensky 2005; 
Roncador, 2005). Activity of antigen-driven IL-10 secreting Treg cells does not seem to 
need FoxP3 (Vieira, 2004), but requires IL-10 and TGF-β (Groux, 1997). Treg cells of 
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the CD4+CD25high phenotype have been recently reported in TB patients, and an increase 
in frequency of these cells, together with elevated mRNA expression of FoxP3, is 
observed in the peripheral blood of these patients (Guyot-Revol, 2006). The authors 
suggest that Tregs expanded in patients with TB may contribute to suppression of 
immune responses against TB. In a murine study, however, antibody-mediated depletion 
of CD25+ cells prior to pulmonary infection with Mtb and BCG does not affect bacterial 
burden or pathology. The authors interpret this as implying a minor role for Tregs in the 
pathogenesis of Mtb infections in mice (Quinn, 2006). 
 
1.5 Roles of cytokines in M. tuberculosis infection 
Cytokines are produced by activated immune cells, often in response to an infection in 
general, or specifically to an antigen. Given the chronicity of Mtb infection, the role of 
cytokines in polarising the immune response at the inflammation site is significant as 
demonstrated by cytokine gene-deficient mice. The cytokines of relevance to this study 
will be described here. 
 
1.5.1 Interferon γ (IFN-γ) 
IFN-γ is a key cytokine required for protection in Mtb infections. It is produced by NK 
cells early, and later by activated CD4+, CD8+ and γδ T cells, in Mtb infections. Although 
insufficient in limiting Mtb infections by itself, IFN-γ plays an important role of 
activating macrophages by inducing phagosome maturation and upregulating their 
antimicrobial molecules, such as iNOS (inducible nitrogen oxide synthase), reactive 
nitrogen intermediates and reactive oxygen species, against intracellular Mtb. Humans 
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who have genes defective for IFN-γ are susceptible to serious mycobacterial infections 
(Cooper, 1993; Jouanguy, 1996). In addition, IFN-γ gene disruption murine experiments 
proved a high susceptibility to Mtb in these mice (Cooper, 1993; Dalton, 1993; Flynn, 
1993). However, IFN-γ is weakly produced in patients with active pulmonary TB 
(Onwubalili, 1985; Vilcek, 1986), and some authors have suggested that this may be, in 
part, a cause for their susceptibility. 
 
Human studies in Malawi have demonstrated that among BCG vacinees, increases in 
IFN-γ responses to Mtb antigens were highest among those with low initial 
responsiveness to environmental mycobacterial (Env) antigens (Black, 2001a). Later 
studies done by the same group showed that prior to BCG vaccination, Malawi residents 
already have a higher IFN-γ response to Mtb purified protein derivative (PPD) and some 
Env species than UK individuals, likely due to Env sensitisation (Black, 2002; Weir, 
2006). An increased frequency of IFN-γ responses to Env was also observed in Malawi, 
but not in the UK, over time in non-vaccinated controls, reflecting the higher level of 
natural exposure to Env in Malawi than the UK (Weir, 2006). Different levels of natural 
exposure to Env have an impact on subsequent BCG vaccination, which will be discussed 
later. 
 
1.5.2 Interleukin 4 (IL-4) 
There have been studies showing increased expression of the Th2 cytokine IL-4 in human 
TB patients as well as murine TB models (Hernandez-Pando, 1996; Seah, 2000; van 
Crevel, 2000; Lienhardt, 2002). Some roles that IL-4 may play in immunity against TB as 
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well as in immunopathology have been suggested. Findings include activation of an 
inappropriate type of macrophages, a decrease in Toll-like receptor 2 (TLR2) expression 
and signalling, in addition to a downregulation of inducible nitric oxide synthase (iNOS) 
by IL-4 (Bogdan, 1994; Krutzik, 2003; Kahnert, 2006). IL-4 knockout (KO) studies in 
Balb/c mice have demonstrated that IL-4 KO mice were better able to control bacterial 
replication and produce Th1 cytokines like IFN-γ to combat the disease progression of 
TB than control mice (Hernandez-Pando, 2004). These findings point towards IL-4 as a 
cause for decreased immunity and increased immunopathology in TB. 
 
1.5.3 Transforming growth factor β (TGF-β) 
It has been shown that Mycobacterium vaccae–induced Treg cells priming anti-
inflammatory responses to ovalbumin produce IL-10 and transforming growth factor-β 
(TGF-β) (Zuany-Amorim, 2002). These cytokines have been described to have 
immunosuppressive roles and are produced by Treg cells. Treg cells have been shown to 
be expanded in TB patients and likely have roles in suppression of Th1-type immune 
responses in TB disease (Guyot-Revol, 2006). IL-10 and TGF-β have been suggested to 
down-regulate host immune responses against TB in lungs of human patients, which then 
lead to overt disease (Bonecini-Almeida, 2004). TGF-β has also been indicated, in vitro, 
to play a part in suppressing T cell responses to mycobacterial antigens in peripheral 
blood mononuclear cells (PBMCs) (Hirsch, 1996; Ellner 1997; Hirsch, 1997; Toossi and 
Ellner 1998). Some mechanisms behind the suppressive role of TGF-β include inhibition 
of lymphocyte proliferation and function, suppression of IL-2 production and blocking of 
IFN-γ –induced macrophage activation (Allen, 2004; Hernandez-Pando, 2006). A recent 
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study by Hernández-Pando et al (2006) demonstrated that the administration of TGF-β 
antagonist and cyclooxygenase inhibitor in mice controlled pulmonary TB to a similar 
extent as anti-microbial treatment alone. These experiments suggest that TGF-β is an 
important player in the defective cell mediated immunity (CMI) that leads to TB 
progression.  
 
1.5.4 Interleukin 10 (IL-10) 
There is evidence to show that IL-10 antagonises anti-microbial effector functions of 
macrophages and reduces the presentation of major histocompatibility complex (MHC) 
class II-peptide complexes at monocyte plasma membranes (Koppelman, 1997; Redpath, 
2001; de la Barrera, 2004). A recent study found that IL-10 in BCG-infected cells inhibits 
cathepsin S-dependent processing of the MHC class II invariant chain in human 
macrophages, therefore escaping immune surveillance by inhibiting the export of mature 
MHC class II molecules to the cell surface and reducing the presentation of 
mycobacterial peptides to CD4+ T cells (Sendide, 2005). Elevated levels of IL-10 are also 
seen in mice made susceptible to Mtb due to the absence of the transcription factor T-bet, 
implying that IL-10 has a part to play in TB progression as well (Sullivan, 2005). 
 
1.6 BCG as a vaccine 
Currently, BCG is the only available human vaccine against TB, and has seen almost a 
century of human usage. BCG is an attenuated strain of M. bovis, and was obtained after 
many years of continuous in vitro passage of a virulent M. bovis strain. In spite of the 
long history, it is not yet clear what are the exact immune mechanisms underlying 
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protection conferred by this vaccine. More importantly, scientists are now intensively 
investigating reasons why BCG has poor efficacy against adult forms of TB. The 
protective efficacy of BCG varies dramatically across different parts of the world – a 
geographical variation in BCG efficacy is observed, with between 0 – 80% efficacy noted 
in different areas. BCG-attributable protection is especially low in developing countries, 
such as parts of Asia and Africa, which are also the areas of high TB incidence.   
 
BCG has consistent ‘efficacy’ as a vaccine in murine models of TB – in this field, this is 
defined with respect to the ability to diminish Mtb bacterial burden upon subsequent TB 
infectious challenge – but even in mice, BCG vaccination never results in host 
elimination of subsequent TB infection.  Other candidate TB vaccines have not even been 
able to outshine this ‘protection’ provided by BCG in mice (Olsen, 2000; Skeiky, 2000; 
Orme, 2001; Doherty, 2004). In mice, BCG does induce high levels of IFN-γ production, 
and it has been argued that the magnitude of this response may be an immune correlate of 
protection (Al-Attiyah, 2004; Castanon-Arreola, 2005; Hovav, 2005). However, it is also 
evident that some candidate TB vaccines which elicit stronger IFN-γ responses than BCG 
are nonetheless less protective than BCG in terms of reducing TB bacterial burden. 
(Skinner, 2003). 
 
1.7 Environmental mycobacteria (Env) 
There are numerous species of mycobacteria that are free-living and ubiquitous in soil 
and open waters, termed Env, which are also known as non-tuberculous mycobacterium. 
Many of these are opportunistic pathogens. They rarely cause human disease, except 
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upon direct inoculation, but are common pathogens to people with  
immunocompromising conditions (Primm, 2004). 
 
1.8 Effect of environmental mycobacteria (Env) exposure on subsequent BCG 
vaccination 
Recent studies have proposed that immune modulation through exposure to Env affects 
the efficacy of BCG. These non-pathogenic mycobacteria belong to the same genus as 
Mtb and BCG, and many are genetically closely related to BCG. Human epidemiological 
studies have shown circumstantial evidence that efficacy of BCG vaccination is reduced 
in populations with high levels of exposure to Env (Black, 2001a; Black, 2002). BCG-
vaccinated individuals in the United Kingdom (UK) have post-vaccination increases in 
IFN-γ responses to PPDs from different species of Env, and the degree of change is 
correlated to the relatedness of the Env species to BCG, thereby providing evidence that 
memory T cells responding to BCG cross-react with Env antigens (Weir, 2006).  The 
efficacy of BCG has been demonstrated to be better in the UK compared to rural African 
areas such as Malawi, where exposure to Env is believed to be higher. The prevalence 
and magnitude of sensitivity to PPDs from Env before BCG vaccination have been 
shown to be higher in Malawi individuals than those in the UK, affirming that Env 
exposure is indeed higher in Malawi than in the UK (Black, 2001b, 2002, Weir, 2003). 
Malawi adults, upon BCG vaccination, have only moderate increases in IFN-γ and 
delayed type hypersensitivity (DTH) responses, while greater increases are seen in the 
UK individuals. The difference in BCG-attributable increases in IFN-γ and DTH 
responses together with the difference in Env exposure between these two populations 
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indicate a possible role of Env in interfering with the protective efficacy of BCG. The 
authors suggest that Env could possibly confer a level of immune protection to TB which 
subsequent BCG vaccination does not surpass. As a result, there may be little additional 
protection observed post-BCG in these populations, but the overall level of protection is 
still inadequate to completely prevent adult forms of TB. This ‘masking hypothesis’ thus 
suggests that Env-generated immunity masks the effects of BCG (Andersen and Doherty, 
2005). 
 
A second hypothesis – the ‘blocking’ hypothesis’ – is based on murine studies showing 
that prior sensitisation with certain species of Env reduces the replication of live BCG in 
the host, possibly through immune responses to antigens that are cross-reactive with BCG 
antigens (Buddle, 2002; de Lisle, 2005; Demangel, 2005). Brandt et al (2001) show that 
in mice exposed to live Env, subsequent BCG vaccinations result in transient immune 
responses that limit BCG multiplication, thereby reducing its numbers, and are unable to 
protect against TB. Another study also demonstrated that exposure to live Env, which are 
cleared with antibiotic treatment, followed by immunisation with BCG results in 
limitation in the replication of BCG in these mice as well as reduced protective effects of 
BCG against TB (Demangel, 2004). These studies support the ‘blocking’ hypothesis, 
which attributes the lack of BCG activity to the possibility that with prior Env exposure, 
memory responses cross-reactive with BCG antigens result in limitation of BCG 
multiplication thereby attenuating the desired effects of the live vaccine in continuously 
stimulating T cell responses. However, the specific nature of immunity invoked by Env 
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and therefore the reasons why the BCG showed reduced replication in Env-sensitised 
hosts were not addressed in those studies. 
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CHAPTER 2   AIMS AND OBJECTIVES 
 
Epidemiological evidence suggests that the efficacy of Mycobacterium bovis bacille 
Calmette- Guérin (BCG) as a tuberculosis vaccine may be influenced by prior host 
sensitisation to environmental mycobacteria (Env). Recent work in our lab showed that 
mice sensitised with M. chelonae had cytotoxicity responses against autologous 
macrophages infected with BCG. Such cross-protective cytotoxic responses were most 
significant with M. chelonae amongst many Env species tested, and this formed the basis 
for the use of M. chelonae in our current project. This prior work of our lab thus suggests 
that it is cytotoxicity against BCG-infected macrophages that could be responsible for the 
observed reduction in BCG replication in Env-sensitised mice. However, another 
hypothesis may also be possible to explain the lack of BCG efficacy after Env 
sensitisation. A study by Zuany-Amorim et al (2002), showed that sensitisation with 
heat-killed M. vaccae (an Env species) gave rise to ovalbumin-specific regulatory T cells 
(Treg) that reduced the airway inflammation in mice with ovalbumin-induced 
eosinophilic airway inflammation. In our lab, after M. chelonae sensitisation followed by 
intranasal BCG administration, both lung BCG load as well as recruitment of 
inflammatory cells in these mice were markedly decreased. We showed that the adoptive 
transfer of a subset of T cells from Env-sensitised mice was responsible for this effect 
(Zhang et al, manuscript in preparation). This demonstrated that Env species, such as M. 
chelonae, have immunomodulatory effects that reduce the immune response to BCG.  
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In this project, murine M. chelonae sensitisation followed by intranasal BCG infection 
was used as the model to understand the phenomenon in humans of diminished vaccine 
efficacy of BCG after exposure to Env. We wished to test the hypotheses that 
cytotoxicity plays a role in immune responses induced by M. chelonae (as a 
representative of Env) against BCG, and that there was also a regulatory T cell response 
induced by Env sensitisation.  
 
The objectives of this study are: 
1) To determine if Env sensitisation in a murine model primes for cytotoxicity 
against BCG-infected cells, and the cell subsets and cytokines involved. 
2) To examine evidence for a regulatory T cell response invoked by Env 
sensitisation, and the functional consequences on subsequent live BCG exposure. 
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CHAPTER 3  MATERIALS AND METHODS 
 
3.1 Mice  
BALB/c mice between 5 – 6 weeks old were purchased from the Centre for Animal 
Resources (CARE) and Biological Resources Centre (BRC). Mice were maintained in the 
departmental animal facility, housed in individual isolator cages (Alternative Design, US) 
with filter tops. Food and water were supplied ad lib, and autoclaved beddings were 
changed twice a week. All experiments were carried out with the approval of the 
institutional animal care and use committee. 
 
3.2 Bacteria 
Mycobacterium chelonae derived from clinical samples cultured on Lowenstein-Jensen 
media, was a generous gift from Dr Pam Nye, University College London Hospitals 
(UK). Mycobacterium bovis BCG (Pasteur) vaccine strain was donated by Dr William 
Jacobs, Jr (Albert Einstein College of Medicine, USA). All species were subsequently 
cultivated on Middlebrook 7H10 agar (refer to appendices), supplemented with oleic 
acid-albumin-dextrose-catalase (OADC; Difco), and single colonies picked for growing 
in Middlebrook 7H9 broth (Difco) + 20 % Tween 80 (refer to appendices). Some cultures 
were stored in 50 % glycerol aliquots at -80 °C before use. 
  16  
 3.3 Preparation of heat-killed and live mycobacterial cultures 
Mycobacterium bovis Bacille Calmette-Guérin (BCG) and Mycobacterium chelonae 
broth cultures were grown to mid-log phase. Required volumes of culture were 
subsequently centrifuged at 2500 x g for 10 min and washed twice with sterile phosphate 
buffered saline (PBS, prepared with nanopure water) before re-suspension in PBS. This 
bacterial suspension was passed via a syringe through a 27 G needle to reduce clumping, 
before absorbance was measured at 600 nm to estimate bacterial numbers (1 A600 ~ 2x108 
bacteria). Bacterial suspensions were diluted to obtain 1 x 106 cells/ 10 μl PBS or 1 x 107 
cells/ 50 μl PBS for murine immunisation and lymphocyte restimulation respectively. 
These preparations were subsequently heat-killed at 95 °C for 10 min, and stored at -20 
ºC until use. For intranasal infection of mice, 0.15 - 1 x 106 live BCG were re-suspended 
in a final volume of 10 μl PBS. Such preparations were kept at 37 ºC prior to infection. 
All BCG preparations were subjected to purity check and counting of the actual colony-
forming units (CFU) – bacteria were re-suspended in Middlebrook 7H9 and serial 
dilutions plated on Middlebrook 7H10 agar. Bacterial colonies were counted 3 weeks 
after incubation at 37 °C. 
 
3.4 Murine immunisation and live BCG challenge 
Mice were immunised thrice at weekly intervals with 106 heat-killed M. chelonae in 100 
μl sterile PBS, prepared as described above, via the intraperitoneal (i.p.) route. If live 
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BCG was given, it was prepared with sterile PBS. The infected mice were sacrificed at 
one week or three weeks post-infection.    
 
3.5 Trypan Blue exclusion assay 
To count viable murine cells, 10 μl of cell suspension was added to 10 μl of 0.04 % 
trypan blue dye (Merck, Germany) at room temperature and mixed by pipetting. 
Subsequently, 10 μl of the mixture was loaded into a single chamber of a 
haemocytometer for cell counting. Non-viable cells were stained blue because of their 
inability to limit the entry of the blue dye, while viable cells remain clear. Only unstained 
cells were enumerated. 
 
3.6 Isolation of murine peritoneal macrophages 
Mice were sacrificed by CO2 asphyxiation at appropriate time points. To harvest 
peritoneal macrophages, 5 ml of ice-cold RPMI 1640 supplemented with 2 mM L-
glutamine (RPMI) + 10 % fetal bovine serum (FBS) was injected into the peritoneal 
cavity via an 18G needle and the peritoneum gently massaged before withdrawal of the 
peritoneal fluid. This process was repeated with a new needle, and all peritoneal fluid was 
subsequently kept on ice, until use. Cell suspensions were centrifuged at 400 x g for 10 
min at 4°C, and cell pellet re-suspended in 2 ml of RPMI + 10 % FBS. Cell numbers 
were obtained and cells seeded into tissue culture wells to obtain adherent cells after 
overnight culture. 
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 3.7 Isolation of murine splenocytes and lung tissue 
Lung tissue was subjected to enzymatic digestion in 1 ml of 0.34 PZ-U/ ml collagenase 
(NB 4 standard grade; Serva, Germany) at 37 °C for 1 h, but splenocytes were not 
treated. Both organs were homogenised through sterile 40 μm nylon cell strainers (BD 
Falcon). The cells were suspended in 5 ml of RPMI + 5 % FBS, centrifuged at 350 x g 
for 10 min, and the pellet re-suspended in 1 ml of 0.17 M NH4Cl (refer to appendices) for 
90 sec to lyse the red blood cells. The cells were immediately diluted in an additional 5 
ml of RPMI + 5 % FBS, centrifuged at 350 x g for 10 min, and cells re-suspended in 
RPMI + 5 % FBS before cell numbers were counted.  
 
B cells were depleted from splenocytes using Dynabeads Mouse pan B (B220; Dynal 
Biotech ASA, Oslo, Norway) at 1 bead: 1 splenocyte ratio. According to the 
manufacturer’s instructions, briefly, splenocytes were labelled with anti-CD19 linked to 
magnetic beads, in RPMI + 5 % FBS for 30 min at 4 °C. After negative magnetic 
selection, a portion of the B cell-depleted splenocytes were seeded at 2 x 106 cells/ ml of 
RPMI + 5 % FBS in a 24-well plate (Greiner) for antigen restimulation while the 
remaining B cell-depleted splenocytes underwent further CD4-sorting (see below). All 
experiments utilising murine splenocytes were derived following this treatment. 
 
3.8 Positive cell selection using magnetic beads 
CD4+ and CD4- T lymphocytes from B cell-depleted splenocytes were derived using the 
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CD4+ positive selection MACS kit (Miltenyi Biotec). Splenocytes were incubated in 
staining buffer, with CD4-specific antibodies coupled to magnetic beads at 4 °C for 15 
min in the dark, according to manufacturer’s instructions. Following processing through 
the AutoMACS (automated Magnetic Cell Sorting; Miltenyi Biotec) column, 
magnetically-labelled cells were separated from non-labelled cells using the ‘positive 
selection’ mode. The labelled and non-labelled cells were collected from the positive and 
negative ports respectively, in 5 ml of RPMI + 5 % FBS. Cells were subsequently 
counted, centrifuged at 350 x g for 10 min before re-suspension in appropriate volumes 
of RPMI + 5% FBS for experiments.  
 
3.9 Bronchoalveolar lavage (BAL) 
Bronchoalveolar lavage (BAL) was performed immediately after sacrificing the mice 
subjected to BCG challenge. Sterile PBS (600 μl) was instilled via the trachea into the 
lungs twice, and the BAL fluid withdrawn and centrifuged at 600 x g for 5 min. The 
supernatant was stored at -20 °C prior to cytokine analysis whereas the cells were re-
suspended in 160 μl of PBS, counted and diluted, if required, to a maximum 
concentration of 2 x 105 cells/ 150 μl PBS. The 150 μl cell suspension was loaded onto 
the Cytospin 3 (Thermo Shandon Fisher Scientific) centrifuge and cells concentrated onto 
a single spot on glass slides after spinning at 550 rpm for 5 min. The slides were heat-
treated, fixed in methanol for 15 min and stained with 10% Giemsa (Applichem, 
Germany) for 20 min. The number of macrophages, neutrophils, lymphocytes and 
eosinophils were obtained by visually counting the cells under the microscope, and their 
adjusted numbers in 1 ml of BAL fluid was calculated.    
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 3.10 Cytokine analysis by ELISA 
Total splenocytes, CD4+ and non-CD4+ (CD4-) splenocytes were seeded at 2 x 106 cells/ 
ml in each well of a 24–well plate for re-stimulation. After 48 h of stimulation with heat-
killed M. chelonae, supernatants harvested from cell cultures were assayed by Enzyme-
Linked Immunosorbent Assay (ELISA) for the presence of IFN-γ, TGF-β (BD 
Pharmingen), IL-10 (R&D Systems) and IL-2, IL-4 (BioLegend), using the respective 
kits according to manufacturer’s instructions. All assays were based on the sandwich 
ELISA. The ELISA plate (Co-star or BD Falcon) wells were coated with diluted 
cytokine-specific capture antibody overnight, blocked using assay diluent, and 
subsequently incubated with culture supernatant or diluted recombinant cytokine 
standards. Biotinylated antibodies specific for the respective cytokines were used as the 
detecting antibody, and streptavidin- or avidin- horse radish peroxidase (HRP) were used 
in conjunction with TMB substrate to produce a colormetric change. The absorbance was 
read at 450 nm with a correction wavelength of 570 nm using the Magellan ELISA reader 
(Tecan, Switzerland) and the amount of cytokine in the samples was derived by 
interpolation from the standard curve. The detection limit for the ELISA assay used was 1 
pg/ ml for IL-4 and IL-2, 31.2 pg/ ml for IFN-γ and 62.5 pg/ ml for TGF-β .  
 
3.11 BCG killing assay by peritoneal macrophages 
Freshly isolated peritoneal cells were seeded at 2 x 105 cells/ 200 μl RPMI + 5% FBS in 
96-well round-bottom tissue culture plates and incubated overnight at 37 °C in 
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humidified air containing 5% CO2. The non-adherent cells were removed the next day, 
and fresh medium added with ferric ammonium citrate (FAC) at a working concentration 
of 50 μg/ml (refer to appendices). Wells were included for counting macrophages seeded 
after trypsinisation of the adherent cells.  
 
The macrophages in each of the test wells were infected with live BCG in 10 μl of 
Middlebrook 7H9 medium, at a MOI of 10:1, for 4 hours at 37 °C with 5 % CO2.  
Middlebrook 7H9 medium alone was added to negative control wells. At the end of the 4 
hour incubation, extracellular BCG was removed by washing the wells gently with 100 μl 
of RPMI + 5 % FBS. Macrophages were lysed by adding 200 μl of freshly prepared 0.1% 
saponin (Sigma-Aldrich). The supernatants from each well were centrifuged at 2000 x g 
for 10 min, and re-suspended in 100 μl of 7H9 medium. Serial dilutions of the resultant 
bacteria suspension were cultured in triplicates and colonies counted after 3 weeks of 
incubation. 
 
3.12 Flow Cytometry 
3.12.1 Cell surface markers 
Lung cells designated for flow cytometry were PBS-washed and 0.5 – 1 x 106 cells/tube 
re-suspended in 50 μl of staining buffer (PBS + 0.5 % bovine serum albumin (BSA; 
Sigma). The cells were stained for various cell surface markers by adding 2 μl of relevant 
antibodies per tube and incubated for 30 min on ice in the dark. Unbound antibodies were 
removed by washing with 1 ml of ice-cold PBS, and cells were fixed in 4 % 
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paraformaldehyde. Samples were kept at 4 °C in the dark before analysis by the flow 
cytometer (Cytomics FC500, Beckman Coulter). Fluorescence was analysed by 
measuring fluorescent intensity of the fluorochromes used, i.e. fluorescein isothiocyanate 
(FITC), phycoerythrin (PE), allophycocyanin (APC) or phycoerythrin-cyanate 7 (PE-
Cy7).  
 
Mouse specific mAbs CD3-FITC (hamster IgG1, κ), CD4-APC (rat IgG2a, κ), CD3-PE 
(hamster IgG1 κ), CD11b-FITC (rat IgG2b κ), CD11c-APC (hamster IgG1) were 
purchased from BD Bioscience, while biotin-CD8 (rat IgG2a, κ), streptavidin PE-Cy7, 
and CD49b/Dx5 (pan-NK) –FITC (rat IgM, κ) were purchased from BioLegend, and 
F4/80-biotin (rat IgG2b, κ) from Serotec. These mAbs were used with relevant isotype 
controls. CD49b (Dx5) is mainly expressed on NK cells and NKT cells, and can be used 
for the identification and isolation of NK cells. CD3, CD11b, F4/80 and CD11c are 
cellular markers for determining lymphocytes, neutrophils, macrophages and dendritic 
cells respectively. To determine absolute cell numbers of each cell type, the samples were 
spiked with fixed volumes of known concentrations of Flow-Count Fluorosphere® 
(Beckman Coulter) which provided the reference for cell numbers. 
 
3.12.2 Intracellular cytokine and perforin staining 
Lung cells for perforin staining were used directly, while those for cytokine staining were 
seeded at 1 x 106 cells in 1 ml of RPMI + 10 % FBS per well in 24 well flat-bottom tissue 
culture plates. In each well, 1 μl of 10 mM ionomycin and 200 μg/ml of phorbol 
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myristate acetate (PMA), in the presence of 3 μM monensin (Sigma), were added. After 6 
h of culture, the cells were centrifuged at 300 x g, 4 °C for 10 min, washed once in 1 ml 
of ice-cold staining buffer, surface stained and fixed for 5 min as described above. The 
cells were then permeabilised in 1 ml of PBS + 0.1 % saponin + 1 % FBS (PBS-S), and 
incubated in 50 μl of PBS + 0.1 % saponin + 0.1 % BSA (PBS-S/BSA) for 30 min on ice. 
Cells were subsequently stained in the dark with IL-10 PE, IFN-γ-PE or perforin-PE 
mAbs in PBS-S/BSA for 30 min at 4 °C, washed with PBS-S and finally re-suspended in 
200 μl of PBS/BSA. The anti-mouse mAbs used were IL-10-PE (rat IgG2b, κ, 
BioLegend) or IFN-γ-PE (rat IgG1 κ, BD Bioscience) or perforin-PE (eBiosciences), 
with relevant isotype controls. Samples were then analysed on the flow cytometer within 
24 h. 
 
3.13 Cytotoxicity assay 
3.13.1 Principle of assay  
A non-radioactive CytoTox 96® Assay kit (Promega) was used to measure cell-mediated 
cytotoxic responses following antigen stimulation. The CytoTox 96® Non-radioactive 
Assay is a colorimetric assay that quantitatively measures lactate dehydrogenase (LDH), 
a stable cytosolic enzyme that is released upon cell lysis. The conversion of a tetrazolium 
salt (INT) into a red formazan product by LDH released in culture supernatants was 
measured by a 30 min coupled enzymatic assay. The amount of red formazan formed is 
proportional to the amount of LDH released, which is also proportional to the number of 
lysed cells when the appropriate controls were subtracted. The amount of the formazan 
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was measured at 490 nm, with the reference wavelength at 650 nm. The percentage 
cytotoxicity was calculated as: 
 
% Cytotoxicity  
= (Experimental – Effector Spontaneous – Target Spontaneous) × 100) 
           Target Maximum – Target Spontaneous 
3.13.2 Cytotoxicity assay experimental set-up 
Freshly isolated murine peritoneal cells were seeded in triplicates at 1 x 105 and 2.5 x 105 
in 200 μl of RPMI + 5 % FBS for PBS- and M. chelonae- immunised mice respectively, 
in 96-well round-bottom tissue culture plates. The adherent cells after overnight culture 
were used as target cells. Separately, to generate effector cells, total B cell-depleted 
splenocytes were seeded at 1.5 x 106 cells/ ml in tissue culture flasks, while CD4+, CD4- 
and total B-cell depleted splenocytes were seeded at 2 x 106 cells/ ml in 24 well tissue 
culture plates for antigen stimulation. 
 
After 48 h of antigen stimulation using heat-killed M. chelonae at a bacteria to cell ratio 
of 10:1, non-adherent effector cells were harvested for viability count, and the culture 
media replaced with fresh RPMI without phenol red (Invitrogen) + 2 % FBS + FAC at a 
working concentration of 50 μg/ml. To evaluate adherent cell numbers, in certain wells, 
these cells were trypsinised and counted by trypan blue exclusion. Target (adherent) cells 
were infected with live M. bovis BCG at an infection ratio (MOI) of 10:1, with added 
FAC at a working concentration of 50 μg/ml to enhance intracellular mycobacteria 
growth. Extracellular bacteria were removed after 4 hours by gently aspirating the 
supernatant and washing the wells once with fresh complete media. The effector and 
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target cells were then co-cultured at an effector to target cell ratio of 10:1 and the entire 
plate was centrifuged at 250 x g for 4 min to allow for maximum contact between the 
effector cells and target macrophages. The plate was then incubated for 12 h at 37 °C in a 
humidified chamber with 5 % CO2. At the end of the co-culture, the plate was again 
centrifuged at 250 x g for 4 min to obtain the cell-free supernatant. Certain control wells 
were also set up – effector cells added to wells without target cells (‘Effector 
Spontaneous’), target cells without effector cells (‘Target Spontaneous’), and target cells 
vigorously scraped off the plate, subjected to freeze-thawing for 10 sec to lyse cells 
completely (‘Target Maximum’).  
 
Fifty microlitres of supernatant from each well were transferred into 96-well flat-bottom 
non-sterile plates and 50 μl of reconstituted substrate mixture from the assay kit was 
added to each well for 30 min at room temperature in the dark. Thereafter, 50 μl of stop 
solution was added. Intensity of colour change in individual wells was measured using 
the Magellan ELISA Reader (Tecan) at 490 nm with reference wavelength at 650 nm and 
the percentage cytotoxicity was calculated according to the formula given above.  
3.14 Statistical analysis 
Means of triplicate well assays were compared using a two-tailed Student t test. Where 
the distribution of data (especially from replicate mice) did not conform to a normal 
distribution, the medians of the experimental groups were compared using the non-
parametric Mann-Whitney U test, and the 25th and 75th percentiles were described for the 
distribution. Differences between groups were considered statistically significant when p 
< 0.05. 
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CHAPTER 4   RESULTS 
 
4.1 Distribution of inflammatory cells in lungs of BCG-infected mice  
The distribution of inflammatory cells in the lungs of PBS- and M. chelonae -immunised 
mice following BCG infection was examined. Three weeks after intranasal BCG 
instillation, cells in the bronchoalveolar lavage fluid (BALF) of infected mice were 
concentrated on slides and the number of macrophages, eosinophils, lymphocytes and 
neutrophils counted, based on their morphology (Fig. 1).  Absolute cell counts of total 
lung cells, dendritic cells (DCs), neutrophils, T cells and macrophages extracted from the 
inflamed whole lung tissue 1 week post-challenge were measured by flow cytometry 
(Fig. 2). 
 
In the BALF, overall there was a lower number of inflammatory cells induced by BCG 
infection in M. chelonae-sensitised mice compared to control mice (Fig. 1B), although 
the differences were not statistically significant. The absolute number of total cells, DCs, 
neutrophils, T cells and macrophages in the inflamed lung tissue 1 week after BCG 
infection was also lower in M. chelonae-immunised mice compared to control mice (Fig. 
2). This was especially evident in total cell count and macrophage count, where there was 
an approximately 2-fold difference between M. chelonae-immunised and control mice 
(p<0.05, Fig. 2). 
 
  27  



























Fig. 1: Cell counts of immune cells in the bronchoalveolar lavage fluid (BALF) of M. 
chelonae (M.che) sensitised and control (PBS) mice after BCG infection. BALF of 
immunised and control mice 3 weeks after BCG infection was obtained by flushing the 
lungs with PBS. Cells from the BALF were concentrated on glass slides, Giemsa 
stained, and cell numbers enumerated under the microscope. A: Immune cells were 
differentiated according to their morphology. M: macrophage, N: neutrophil, L: 
lymphocyte, E: eosinophil. B: Number of different immune cell types per ml of BALF. 
Data represents an average of four individual experiments comprising four mice per 
experimental group. Results are expressed as medians, 75th and 25th percentiles. 
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Fig. 2: Absolute cell count of immune cells in the lungs of M. chelonae 
sensitised and control mice after BCG infection. Lung single-cell suspensions 
from immunised (M.che) and control (PBS) mice 1 week post BCG infection 
were stained with monoclonal antibodies against CD11c (dendritic cells, DC), 
CD3 (T cells), CD11b (neutrophils) and F4/80 (macrophages), and analyzed by 
flow cytometry. Fluorospheres of known concentration were used concurrently 
to obtain an absolute cell count. The figure represents an average of two 
separate experiments comprising four mice per experimental group. Results are 
expressed as medians, 75th and 25th percentiles. Statistical significance was 
determined by non-parametric Mann Whitney-U test. *p<0.05 comparing 
immunised with control mice. 
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In order to further evaluate the distribution of possible effector immune cells in the 
inflamed lung, the distribution of cells with particular markers of interest, namely CD3 (T 
cells), CD4, CD8 (T cell subsets), and CD49b (NK cell) were observed by flow 
cytometry (Tables 1, 2, Fig. 3). The percentage of CD49b+, CD3+ and CD8+CD4- cells in 
the total lung cell population cell populations in the lung remained relatively similar for 
sensitised and control mice (Table 1). The proportion of CD4+CD8- cells in the T cell 
population was significantly higher in M. chelonae-immunised mice compared to control 
mice (p<0.01, M. chelonae- vs PBS-immunised mice; Table 2, Fig. 3). This suggests that 
M. chelonae sensitisation prior to BCG infection induces the expansion of CD4+ cells to a 
greater extent than without pre-sensitisation. 
 
 
Table 1: Percentage of different subsets of cells out of total lung cells. Lung 
single-cell suspensions from immunised and control mice, 1 week post BCG 
infection, were stained with CD3, CD4, CD8 and/ or CD49b (natural killer cell, 
NK)-specific mAbs, followed by flow cytometry. Results are expressed as mean ± 
standard deviation (SD) of two individual experiments. Each experimental group 
comprises four mice. Statistical significance was determined by two-tailed Student’s 
t test. *p<0.01 comparing immunised with control mice. 
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Table 2: Percentage of different subsets of cells out of lymphocyte gate. Lung 
single-cell suspensions from immunised and control mice, 1 week post BCG 
infection, were stained with CD4, CD8 and CD3 (T cell)-specific mAbs, and 
analysed by flow cytometry. Data shown are gated on CD3 cells.The mean ± 1 
SD for the whole experimental group is shown (4 mice per group) and 
incorporates data from two independent experiments. Statistical significance was 
determined by two-tailed Student’s t test. *p<0.01 comparing immunised with 
control mice. 
 
Fig. 3: Distribution of different subsets of cells in the infected lung (gated on 
CD3+ T cells). Data shown are gated on CD3 cells. For the same experiment 
illustrated above, a single representative experiment is shown here, mean data 
for the experimental groups is presented in the table above.  
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4.2 Cytokine expression in different cell subsets in BCG-infected lungs  
 
It was postulated that differential cytokine expression may account for the observed 
differences in inflammatory responses between M. chelonae-sensitised and control mice 
one week after BCG infection. Thus, the percentage of lung T cells producing IFN-γ or 
IL-10 and their surface markers (CD4+ or CD8+) in the infected mice was analysed by 
flow cytometry (Figs. 4-6, Tables 3, 4).  
 
A predominant percentage of IFN-γ producing T cells were CD4+ in both control and 
sensitised mice (CD4+: CD8+ ratio 1.6 and 2.2 respectively; Fig. 4A). M. chelonae-
sensitised mice had a higher proportion of CD4+ cells among T cells producing IFN-γ 
(55.5 ± 5.9 %) compared to control mice (48.1 ± 7.3 %). In particular, among the IFN-γ 
producing T cells, cells of the CD4+CD8- phenotype were of a significantly higher 
proportion in M. chelonae-sensitised mice (45.8 ± 4.8 %) compared to control mice 
(35.75 ± 2.5 %) (p<0.05). 
 
Within each of the CD4+ and CD8+ T cell populations, a higher percentage of IFN-γ+ 
cells was observed in the lungs of sensitised mice compared to control mice (Table 3, 
Fig. 5). This difference was more obvious in the CD4+ T cell population, where 13.3 ± 
0.81 % of CD4+ cells was producing IFN-γ in sensitised mice, as compared to 8.8 ± 2.5 
% in control mice (p<0.05, Fig. 5, Table 3). 
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Fig. 4: Distribution of various cell types among CD3+ cells producing IFN-γ or IL-
10. Lung single-cell suspensions from immunised and control mice, 1 week post BCG 
infection, were stimulated with PMA and ionomycin, and treated with monensin for 6 
h. Cells were stained for expression of  CD4, CD8, CD3, and either IFN-γ or IL-10 
before analysis by flow cytometry. The analysis was focused only on cytokine-
positive cells within the CD3 (T cell) gate. Results for the whole experimental group is 
shown (4 mice per group) and are expressed as mean % of each cell subset out of all 
IFN-γ+ (A) or IL-10+ (B) cells ± 1 SD. Results incorporate data from two independent 
experiments. Statistical significance was determined by two-tailed Student’s t test. 
*p<0.05, **p<0.001 comparing immunised with control mice. 
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In summary, with respect to cytokine production in BCG-infected lungs, CD4+ cells 
comprised the predominant population of cells producing IFN-γ and IL-10. In addition, it 
was generally observed that a higher level of cytokine, in M. chelonae-sensitised than 
control mice, was secreted within the CD4+ and CD8+ populations. 
 
Considering the CD4+ and CD8+ T cell populations separately, a higher percentage of 
cells producing IL-10 was observed in sensitised mice compared to control mice (Fig, 
Table 4, Fig. 6). Within the CD4+ T cell population, 14.4 ± 1.9 % in sensitised mice were 
producing IL-10, as compared to 10.2 ± 2.2 % in control mice, while in the CD8+ 
population, 10.6 ± 1.8 % and 6.7 ± 1.3 % was producing IL-10 for sensitised and control 
mice respectively (Fig. 6, Table 4). 
  
 
A similar trend for CD4+ T cells was observed for IL-10 production. The CD4+ cells were 
predominant over CD8+ cells in the IL-10+ T cell population of both experimental groups 
of mice (CD4+: CD8+ ratio 1.6 and 2.2 respectively in control and M. chelonae-sensitised 
mice; Fig. 4B). Considering only the T cells producing IL-10, M. chelonae-sensitised 
mice had a higher percentage in the CD4+ population (61.6 ± 6.9 %) compared to control 
mice (47.5 ± 7.3 %). This was particularly evident in the CD4+CD8- population (47.1 ± 
0.6 % and 34.0 ± 2.4 % for sensitised and control mice respectively, p < 0.01, Fig. 4B).  
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Fig. 5: IFN-γ production in lung T cell subsets. Lung single-cell suspensions from immunised and control 
mice, 1 week post BCG infection, were stimulated with PMA and ionomycin, and treated with monensin for 6 h. 
Cells were stained for expression of CD4, CD8, CD3, and  IFN-γ before analysis by flow cytometry. (A): 
Distribution of CD4 and CD8 T cells, after gating on CD3 cells, in  PBS and M. chelonae-immunised mice. (B): 
Percentage of IFN-γ+ cells, gated on CD4+CD8- and CD8+CD4- cells. A single representative experiment is 
shown in A and B, the group mean data is presented in the table below. 35 
Table 3: Percentage of CD4+ or CD8+ cells expressing IFN-γ (CD3 gated 
cells). Based on the same experiment described above in Fig. 5, the mean ± 1 SD 
for the whole experimental group is shown (4 mice per group) and incorporates 
data from two independent experiments. Statistical significance was determined 
by Student’s t test. *p<0.05 comparing immunised with control mice. 
  36   
  
        
37      
Fig. 6: IL-10 production in lung T cell subsets. Lung single-cell suspensions from immunised and control mice, 1 
week post BCG infection, were stimulated with PMA and ionomycin, and treated with monensin for 6 h. Cells were 
stained for expression of CD4, CD8, CD3, and  IL-10 before analysis by flow cytometry. (A): Distribution of CD4 and 
CD8 T cells, after gating on CD3 cells, in  PBS and M. chelonae-immunised mice. (B): Percentage of IL-10+ cells, 
gated on CD4+CD8- and CD8+CD4- cells. A single representative experiment is shown in A and B, the group mean data 
is presented in the table below. 
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Table 4: Percentage of CD4+ or CD8+ cells expressing IL-10 (CD3 gated 
cells). For the same experiment illustrated above in Fig. 6, the mean ± 1 SD 
for the whole experimental group is shown (4 mice per group) and 
incorporates data from two independent experiments. Statistical significance 
was determined by Student’s t test. *p<0.05 comparing immunised with 
control mice.  
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 4.3 Distribution of CD4+ and CD4- cells in the spleen 
 
Splenocytes from mice were subjected to red cell and B cell depletion, then magnetically 
sorted into CD4+ or CD4- cells. This was done to compare the cytotoxic activity of the 
two cell populations, in control and M. chelonae-sensitised mice, with and without 
subsequent BCG infection. The relative distribution of the two cell types was first 
assessed by direct cell counting after sorting. As shown in Table 5, the proportions of 
CD4+ and CD4- cells were similar in both sensitised and control mice, and the 








Table 5: Percentages of CD4 (CD4+) and non-CD4 (CD4-) cells in murine splenocytes 
in presence or absence of BCG infection. Single-cell suspensions of splenocytes from 
immunised and control mice were magnetically sorted into CD4 or non-CD4 cell 
portions. Cells were counted and numbers of each cell population calculated as a 
percentage of the total splenocyte cell number. Data are expressed as mean ± 1 SD. 
Results for the whole experimental group is shown (4 mice per group) and incorporates 
data from four (non-infected) and five (BCG infected) independent experiments. 
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 4.4 Cytotoxic activity following BCG challenge 
Prior work in this lab has found that, comparing M. chelonae-immunised and control 
mice subjected to live BCG intra-nasal infection, the BCG load in the lungs of sensitised 
mice was 1 log lower than in control mice, at 3 weeks post-infection. It was postulated 
that this may be due to lymphocytes in M. chelonae-sensitised mice having higher 
cytotoxic activity than those in control mice. Thus, the cytotoxicity of different cell 
fractions in the infected murine spleens, against autologous BCG-infected macrophages 
was investigated.  
 
Cytotoxicity against BCG-infected autologous target cells was measured in splenocytes 
from M. chelonae-immunised and control mice 1 week and 3 weeks following intranasal 
BCG infection. All splenocytes were stimulated with heat-killed BCG for 48 h before 
carrying out the cyotoxicity assay.  
 
At 1 week post-infection, total splenocytes and CD4+ splenocytes from immunised mice 
had similar cytotoxic activity as the same cell subsets from PBS mice (Fig. 7A). CD4- 
splenocytes, on the other hand, showed lower cytotoxicity in sensitised mice, and a 3-fold 
difference was seen between sensitised and control mice (Fig. 7A). In contrast, at 3 
weeks post-infection, M. chelonae-sensitised mice showed 5- and 6-fold higher cytotoxic 
activity in CD4+ and CD4- cells respectively, compared to control mice (Fig. 7B). The 
difference was less marked in the total splenocyte population – there was approximately 
2-fold higher cytotoxicity in sensitised mice (Fig. 7B). 
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Fig. 7: % cytotoxicity attributable to M. chelonae sensitisation. Splenocytes from 
immunised and control mice were sorted into different fractions (CD4+ or CD4-) and 
re-stimulated in vitro with heat-killed M. chelonae. Cytotoxicity of stimulated cells 
against autologous BCG-infected macrophages was quantified. The ratio of 
cytotoxicity exhibited by cells of immunised relative to control mice is shown (i.e. 
cytotoxicity of immunised mice/PBS mice x 100%). Data represent a mean of 3 
independent experiments. The graphs show cells from mice 1 week (A), 3 weeks (B) 
after intra-nasal BCG infection and without BCG infection (C). 
 
 
 4.5 Cytotoxic activity in M. chelonae-sensitised mice  
 
The same experiments, except with heat-killed M. chelonae stimulation for 48 h, were 
performed in the sensitised and control mice without BCG challenge, to see if this 
differential cytotoxicity already existed prior to the BCG infection. This was proven to be 
true, but the differences were less prominent than in the infected mice. Total splenocytes 
in sensitised mice had almost 2-fold higher cytotoxic activity in comparison to control 
mice (Fig. 7C). For CD4+ and CD4- cell subsets, the M. chelonae-sensitised mice showed 
approximately 2-fold and 1.5-fold higher cytotoxicity respectively, compared to control 
mice (Fig. 7C).  
 
The data on cytotoxicity suggest that M. chelonae sensitisation induces better cytotoxicity 
than without sensitisation, be it at a pre-infection or 3-weeks post-infection stage. It is 
notable though, that at 1 week post-BCG challenge, M. chelonae sensitisation did not 
seem to have an augmentative effect on cytotoxicity compared to control mice. 
 
4.6 Perforin expression in BCG-infected lungs  
 
To look at differential expression of perforin as a marker of cells with cytotoxic potential 
within infected murine lungs, the percentage of CD4+, CD8+ or CD49b+ cells expressing 
perforin in mice with or without pre-sensitisation with M. chelonae was obtained by flow 
cytometry (Fig. 8, Table 6).  
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% of perforin+ cells







Fig. 8: Distribution of perforin producing cells in the lung. Lung single-cell 
suspensions from immunised and control mice, 1 week post BCG infection, were 
stained for expression of CD4, CD8, CD49b (NK cell), and perforin before 
analysis by flow cytometry. The analysis was focused only on perforin-positive 
cells. % of each cell subset within the perforin-expressing population is expressed 
as mean ± 1 SD. Results for the whole experimental group is shown (4 mice per 
group) and incorporates data from two independent experiments. 
 
 When only the perforin-positive cells were considered, the CD4+CD8- were found to be 
the predominant perforin-producing cell type, accounting for approximately 70% of the 
perforin+ cells, in both M. chelonae-sensitised and control mice (Fig. 8). Although not 
statistically significant, sensitised mice had a greater percentage of lung cells expressing 
perforin that were CD4+CD8- than control mice (Fig. 8).  However, in the control mice, 
the CD49b+ population accounted for a higher percentage of the perforin-expressing cells 










Table 6: Percentage of perforin-expressing cells within each immune cell subset 
in the lung. Lung single-cell suspensions from immunised and control mice 1 
week post BCG infection were stained for expression of CD4, CD8, CD49b and 
perforin before analysis by flow cytometry. Each cell subset was gated separately, 
to derive the % of perforin-expressing cells within each cell subset. The mean ± 1 
SD for the whole experimental group is shown (4 mice per group) and incorporates 
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 In both sensitised and control mice, there were 3-fold more CD4+ cells producing 
perforin than CD8+ cells (Table 6). Considering perforin expression within each 
individual cell population (i.e. CD4+, CD8+ and CD49b+), the proportion of CD4+ and 
CD8+ cells producing perforin was similar in sensitised and control mice. However 
within the CD49b+ cell population of M. chelonae-sensitised mice, 14.7% expressed 
perforin, whereas only 7.6% of the CD49b+ cells in control mice were perforin-positive 
(Table 6).  
 
4.7 Macrophage mycobactericidal activity 
 
The mycobactericidal activity of macrophages has an important role in limiting BCG 
growth. As M. chelonae sensitisation is known to result in reduced BCG survival in vivo 
3 weeks after infection, the reduced BCG load could be related to increased cytotoxic T 
cell activity and/or improved macrophage bactericidal activity. To evaluate if the 
macrophages of sensitised and control mice differed in their BCG killing abilities, 
peritoneal macrophages from each group of mice were infected in vitro with BCG for 4 
hours and the surviving bacteria counts were subsequently enumerated by culture. There 
was no difference in the BCG colony-forming units in the wells derived from sensitised 
and control mice (3.1 ± 3.2% vs 3.4 ± 4.3% of the original amount of BCG inoculated for 
PBS- vs M. chelonae-immunised mice), indicating that M. chelonae sensitisation had no 
direct effect on the ability of macrophages to kill BCG. 
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4.8 Cytokine production following M. chelonae sensitisation 
 
It was postulated that the differential cytotoxicity and differential recruitment of immune 
cells to the BCG infected lungs attributable to M. chelonae sensitisation could be related 
to the cytokines produced by the cells post-sensitisation. Cytokines were assayed 1 week 
after M. chelonae or PBS immunisation, as well as 1 and 3 weeks after sensitisation 
followed by intranasal BCG infection. Only splenocytes were studied as it was not 
possible to obtain sufficient lung cells to perform the same assay.  Total splenocytes, 
CD4+ or CD4-splenocytes were cultured for 48 hours with either heat-killed M. chelonae 
(pre-infection mice) or BCG (post-infection mice), and cytokine production measured in 
their supernatants by ELISA. 
 
4.8.1 IL-10 production  
 
IL-10 was investigated as a possible reason for the reduced inflammatory cell recruitment 
to the lungs of infected mice.  In the pre-infection mice, in all the different cell fractions, 
M. chelonae-immunised mice showed significantly higher levels of IL-10 production 
than PBS-immunised mice (p<0.01, p<0.001 and p<0.05 for total splenocytes, CD4- and 
CD4+ cells respectively; Fig. 9A). In cells from M. chelonae-sensitised mice, CD4- cells 
produced the highest amount of IL-10, and this was significantly higher than the levels of 
IL-10 produced by total splenocytes (p<0.05) and CD4+ cells (p<0.001; Fig. 9A). 
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Fig. 9: IL-10 production by splenocytes from M. chelonae-immunised and control (PBS) mice pre- and post-BCG 
infection. Splenocytes from immunised and control mice pre-infection (A), 1 week post-infection (B) and 3 weeks post-
infection (C), were sorted into different fractions (CD4+ or CD4-) and re-stimulated in vitro with either heat-killed M. 
chelonae (S = stimulated) or PBS (US = unstimulated). The concentration of secreted IL-10 in the cell supernatants was 
determined by ELISA. Data shown in A and B represent one of two independent sets of experiments with similar results. 
Results in A and B are expressed as medians, 75th and 25th percentile of four mice per experimental group. Statistical 
significance was determined by non-parametric Mann-Whitney U test. Data shown in B represent a single experiment, 
expressed as mean ± 1 SD. Statistical significance for B was determined by Student’s t test. *p<0.05, **p<0.01, 
***p<0.001 comparing immunised with control mice. §: p<0.05, §§: p<0.01, §§§: p<0.001 comparing between different 
cell types in immunised mice. N.D. = not detectable or below detection limit of the assay kit. 
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 One week following BCG infection, a similar trend was observed. Total splenocytes and 
CD4- cells of M. chelonae-sensitised mice secreted more IL-10 than the corresponding 
fractions in control mice (p<0.01; Fig. 9B). There was no difference in IL-10 production 
by CD4+ cells between immunised and PBS mice. The secretion of IL-10 was 
approximately 5-fold higher in total splenocytes and CD4- cells than CD4+ cells in M. 
chelonae-sensitised mice (p<0.01; Fig. 9B). At 3 weeks post-BCG challenge, IL-10 
levels remained higher for all cell subsets in sensitised mice than control mice (p<0.01 
for total and CD4+ cells; Fig. 9C). However, it is evident that the levels of IL-10 
production were decreasing in the order pre-infection > 1 week > 3 weeks post-infection. 
 
4.8.2 IL-4 and TGF-β production 
 
IL-4 and TGF-β are known to have immunosuppressive roles, and are cytokines 
produced by certain types of regulatory T cells (Mills and McGuirk 2004). In view of the 
reduced inflammatory cell count in lungs of M. chelonae-sensitised mice, these cytokines 
were studied in the splenocytes of these mice and the PBS-immunised mice. Both 
cytokines were not detectable in any of the splenocytes fractions, for both M. chelonae-




  49  
   50  
 
4.8.3 IL-2 production  
 
As IL-2 is produced by proliferating T cells, the IL-2 levels secreted by different subsets 
of splenocytes were studied. In the pre-infection mice, the levels of IL-2 were marginally 
higher in total and CD4+ splenocytes of sensitised mice than PBS mice, but this was not 
statistically significant. IL-2 was not detectable in CD4- cells in both groups of mice (Fig. 
10A).  At both 1 and 3 weeks following BCG challenge, the total splenocytes in M. 
chelonae-sensitised mice produced higher levels of IL-2 than control mice, but the IL-2 
production in CD4- splenocytes was still not detectable (Fig. 10B, 10C). 
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Fig. 10: IL-2 production by splenocytes from M. chelonae-immunised and control (PBS) mice pre- and post-BCG infection. 
Splenocytes from immunised and control mice pre-infection (A), 1 week post-infection (B) and 3 weeks post-infection (C), were 
sorted into different fractions (CD4+ or CD4-) and re-stimulated in vitro with either heat-killed M. chelonae (S = stimulated) or 
PBS (US = unstimulated). The concentration of secreted IL-2 in the cell supernatants was determined by ELISA. Data shown in 
A and B represent one of two independent sets of experiments with similar results. Results in A and B are expressed as medians, 
75th and 25th percentile of four mice per experimental group. Data shown in B represent a single experiment, expressed as mean 
± 1 SD. N.D. = not detectable or below detection limit of the assay kit. 
 
 



































































 4.8.4 IFN- γ production  
 
IFN- γ is known to be a cytokine required for good Th1 type immunity against 
pathogenic mycobacteria, and it is important for activation of macrophages as well as 
cytotoxic T cells. It was postulated that differential IFN- γ production may account for 
the differences between the mice in cytotoxicity and reduction of BCG load.  
 
Mice subjected to M. chelonae sensitisation showed a small deficit of IFN-γ secretion 
relative to control mice in total (p<0.05) and CD4- (not statistically significant) cells in 
the splenocytes (Fig. 11A). On the other hand, CD4+ cells in M. chelonae-immunised 
mice secreted significantly more IFN-γ than control mice (p<0.05; Fig. 11A). Comparing 
IFN-γ levels among the different subsets of splenocytes in the mice post-sensitisation but 
prior to BCG infection, CD4- cells were the predominant IFN-γ producing population, 
secreting the highest levels of IFN-γ (p<0.05 CD4- vs CD4+; Fig. 11A).  
 
In contrast, after BCG infection, M. chelonae sensitisation clearly induced an increased 
secretion of IFN-γ in infected mice. All subsets of splenocytes in sensitised mice had 
higher levels of IFN-γ than in PBS mice at 1 week post BCG infection (p<0.05 and 
p<0.01 for CD4- and CD4+ cells respectively; Fig. 11B). CD4+ cells were the major 
contributor to production of IFN-γ, in the M. chelonae-sensitised mice. However, just as 
for IL-10, the levels of IFN-γ produced in all subsets generally were lower in the mice 1 
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week post-infection than in the immunised mice without infection. Data for mice 3 weeks 
post-infection were not available.  
 
Overall, the cytokine studies suggest that significant levels of IFN-γ, IL-10 and IL-2 
induction in the spleen may be attributable to M. chelonae sensitisation, but compared to 
the lung cytokine-expressing cells, the cell types involved in each organ may be different.  
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Fig. 11: IFN- γ production by splenocytes from M. chelonae-immunised and control (PBS) mice pre-infection and at 1 
week post BCG infection. Splenocytes from immunised and control mice pre-infection (A) and 1 week post-infection (B), 
were sorted into different fractions (CD4+ or CD4-) and re-stimulated in vitro with either heat-killed M. chelonae (S = 
stimulated) or PBS (US = unstimulated). The concentration of IFN- γ secreted in the cell supernatants was determined by 
ELISA. Data shown represent one of two independent sets of experiments with similar results. Results are expressed as 
medians, 75th and 25th percentile of four mice per experimental group. Statistical significance was determined by non-
parametric Mann-Whitney U test. *p<0.05, **p<0.01, comparing immunised with control mice. §: p<0.05, §§: p<0.01 




 CHAPTER 5   DISCUSSION 
 
Why BCG fails to protect against TB in certain human populations is of much research 
interest as it affects current efforts to design an improved TB vaccine. Several studies 
have proposed that pre-exposure to Env has an adverse effect on the efficacy of 
subsequent BCG vaccination (Black, 2001; de Lisle, 2005; Demangel, 2005). However, 
the immunological mechanisms behind this phenomenon have not been explained. Prior 
work in this lab has shown that cytotoxicity against autologous BCG-infected 
macrophages in M. chelonae-sensitised mice was higher than in PBS-immunised control 
mice, and also relative to several other Env. In addition, BCG counts in the lungs 3 weeks 
after intra-nasal infection were 1 log lower in M. chelonae-immunised mice relative to 
control mice. This project therefore sought to further explore the role of cytotoxicity as a 
possible reason for the Env effect on BCG as well as the cell types and cytokines 
involved.  
 
5.1 Cytolytic activity of different cell subsets 
For many years, helper T cells were the main focus in numerous TB-related studies due 
to their ability to activate macrophage killing of intracellular mycobacteria by producing 
IFN-γ. In recent years, however, studies have shown that cytolytic T cells, mainly CD8+ 
cells, also have a role to play in immune responses against Mtb (Sousa, 2000; van 
Pinxteren, 2000). It would seem that lysis of cells harbouring mycobacteria would be an 
effective protective mechanism in mycobacteria infections, hence the importance of 
cytolytic cells against intracellular pathogens such as Mtb. This has clearly been seen in 
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 murine studies where CD8 T cells are necessary for limiting Mtb infection (Flynn, 1992; 
Sousa, 2000; van Pinxteren, 2000; Rolph, 2001), although some studies have also 
suggested otherwise (Mogues, 2001).  
 
In this study, both CD4+ and CD4- splenocytes in M. chelonae-sensitised mice induced 
greater cytotoxicity against autologous BCG-infected macrophages than control mice 3 
weeks following BCG challenge (Fig. 7B). As the ability of macrophages alone in M. 
chelonae-immunised mice to kill BCG was the same as control mice (refer to Section 
4.7), the difference seen in cytotoxicity of sensitised mice is likely to be due to the 
effector cells and not the macrophages.  
 
Natural killer (NK) cells have also been involved in immune responses against TB, as 
shown by increased NK activity in active pulmonary TB patients, as well as an increase 
in NK cell number after BCG or Mtb infection in mice (Yoneda, 1983; Falcone, 1993; 
Junqueira-Kipnis, 2003).  However, as NK cell depletion in mice infected with Mtb does 
not affect bacterial load in the lung, it is proposed that NK cells probably contributes to 
early resistance, but do not have a substantial role in TB immunity (Junqueira-Kipnis, 
2003). Given the low percentage of perforin producing cells that were CD49b+ (Fig. 8), 
as well as the low proportion of CD49b+ cells present in the total lung population (Table 
1), it was likely that the role of NK cells in killing BCG-infected lung cells was small. 
Nonetheless, the percentage of CD49b+ cells producing perforin was higher in M. 
chelonae-immunised than control mice (Table 6), suggesting the possibility that M. 
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 chelonae sensitisation increased the killing activity of NK cells against BCG, thereby 
contributing to clearing of the infection to some extent. 
 
5.2 Cytotoxic CD4+ T cells  
 
CD4+ T cells are commonly known to have ‘helper’ functions. They have been 
characterised as Th1 or Th2 cells based on the cytokines produced, and how these affect 
cellular and humoral immunity. There is now abundant evidence that CD4+ cells can also 
have cytotoxic functions, with lytic capacity observed in cell lines and CD4+ T cell clones 
of mice and humans (Lukacher, 1985; Littaua, 1992; Mahon, 1995; Norris, 2001; Aslan, 
2006). In addition, recent work has reported the presence of cytolytic CD4+ cells in vivo 
in a range of human pathologies such as viral infections (HIV, viral hepatitis and CMV) 
(Appay, 2002; Zaunders, 2004; Aslan, 2006). It is suggested that in infection immunity, 
especially in chronic viral infections, CD4+ CTLs have a major effector role in limiting 
the infection, as the frequency of such CTLs increases with disease, but decreases with 
clearance of infection. Furthermore, CD4+ CTLs have been shown to include antigen-
experienced (i.e. memory) cells in vivo, and are shown to display a surface phenotype and 
functional profile characteristic of terminally differentiated effector cells (Appay, 2002; 
Aslan, 2006). This implies CD4+ CTLs as fully functional effector cells, and not merely 
being present in infections.  
 
This project showed that in sensitised mice, CD4+ cells are the most important subset of 
splenocytes involved in cytotoxicity against BCG-infected cells. This supports prior work 
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 in our lab showing that in the M. chelonae-sensitised mice, the splenocytes that are 
depleted of CD4 cells showed significantly reduced cytotoxicity. The cytolysis mediated 
by CD4+ T cells may act via the perforin-granzyme pathway, since at 1-week post-BCG 
infection, CD4+ cells in the lung comprised the predominant cell subset among perforin-
expressing cells in both M. chelonae- and PBS-immunised mice (Fig. 8). An increased 
frequency of CD4+ CTLs expressing granzymes and perforin, compared to healthy 
controls, is observed in humans with viral infections, indicating perforin as a possible 
mechanism of cytolysis (Aslan, 2006). More directly, cytolytic activity of CD4+ CTLs 
has been shown to be mediated by perforin in an ex vivo experiment, where cytotoxicity 
was markedly reduced upon inhibition of the perforin pathway (Appay, 2002).  
 
It has been reported in murine studies that cytotoxic activity of CD4+ CTLs are primarily 
perforin dependent rather than Fas/ Fas-ligand dependent, but only in the absence of 
CD8+ cells (Williams and Engelhard 1996; Williams and Engelhard 1997).  CD4+ CTLs 
act via both pathways in the presence of CD8+ cells, indicating a possible role of CD8+ 
cells in regulating the perforin-mediated pathway of cytotoxicity (Williams and 
Engelhard 1997). However, it is observed in gld transgenic mice with defective Fas 
ligand, that cytotoxicity of CD4+ cytolytic T cells is substantially reduced, suggesting that 
in other model systems, the Fas /Fas ligand may be the main pathway of murine CD4+-
mediated cytotoxicity (Hanabuchi, 1994; Ju, 1994; Stalder, 1994). This pathway was not 
studied in the current project, and warrants further investigation. To elucidate the 
mechanisms behind the cytotoxic activity of CD4+ cells, it will be useful to inhibit the 
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 different cytolytic pathways, e.g. through the use of anti-Fas antibodies or concanamycin 
A, and subsequently measure the cytotoxicity of CD4+ cells in the future.  
 
5.3 Cytotoxicity is higher at later time-points after BCG infection 
 
As shown in Fig. 7C, M. chelonae sensitisation induced higher cytotoxicity of autologous 
BCG-infected macrophages than PBS-immunised mice in all splenocyte fractions. This 
trend was augmented at 3 weeks post-BCG infection, but was not observed at 1-week 
post-infection (Fig. 7A, 7B). The influence of M. chelonae on immunity following 
subsequent pathogenic mycobacteria (i.e. BCG) exposure is likely to be due to induction 
of memory T cells by M. chelonae — others in our lab have shown that the population of 
CD44+ CD62L- cells is expanded in the sensitised mice. As such, it was likely that the 
higher cytotoxicity observed in sensitised mice compared to control mice pre-infection 
and at 3 weeks following BCG challenge was due to memory T cells cross-reactive to 
common mycobacterial antigens. The difference in cytotoxicity seen between 1-week and 
3 weeks post-BCG challenge could be attributable to the presence of regulatory T cells 
(Treg).  This is evidenced by the higher levels of IL-10 secreted by splenocytes at 1-week 
post-BCG challenge than at 3 weeks in sensitised mice (Fig. 9B, 9C).  These may have 
contributed to the lower inflammatory cell recruitment and thus lower cytotoxicity in M. 
chelonae-sensitised mice at 1-week post-BCG infection. (Figs. 2, 9B) 
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 5.4 Possible induction of regulatory T cells by M. chelonae sensitisation 
M. vaccae (an Env species) induces ovalbumin-specific CD4+CD45RBlow Treg cells that 
secrete IL-10 and TGF-β. These have been shown to reduce the airway inflammation in 
mice with ovalbumin-induced eosinophilic airway inflammation, after sensitisation with 
heat-killed M. vaccae (Zuany-Amorim, 2002). Our present data show that recruitment of 
inflammatory cells to the lungs of M. chelonae -sensitised mice was decreased 1 week 
after BCG challenge, as shown by cell counts in the BALF (Fig. 1) and absolute cell 
counts in the lung (Fig. 2). This could be attributable to an upregulation of Treg cells in 
the lung after M. chelonae sensitisation. 
 
Cells of the CD4+CD25+ phenotype are known to be Treg cells, which secrete IL-10, and 
have been shown to exist in TB patients (Dieckmann, 2005; Guyot-Revol, 2006; 
Shevach, 2006). Extensive flow cytometric phenotyping of cells from M. chelonae-
sensitised mice performed previously in our lab has shown that the sensitisation markedly 
increases the regulatory T cell proportions – these cells are 
CD4+CD25+CD27+Foxp3+CD44+CD62L-. There is some debate as to whether such Treg 
cells actually diminish the anti-mycobacterial immunity of the host, or are simply a 
response to the inflammation induced by TB infection (Guyot-Revol, 2006; Quinn, 
2006). In the lungs of sensitised mice at 1-week post-infection, CD4+ T cells were the 
predominant subset among IL-10 producing cells (Fig. 4B). Moreover, comparing M. 
chelonae- and PBS-immunised mice, the percentage of IL-10+ cells that were CD4+CD8- 
was significantly higher in M. chelonae-sensitised mice (Fig. 4B). M. chelonae 
immunisation also induced a significant increase in the proportion of CD4+ and CD8+ 
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 cells producing IL-10 in the lung (Table 4, Fig. 6). These data provide evidence that at 
the site of BCG instillation, which is also the organ with maximal inflammation, there is 
upregulation of Treg responses that is augmented by prior M. chelonae-sensitisation.  
 
It is intriguing to note that, in contrast to the lungs, the highest production of IL-10 in the 
spleens of these M. chelonae- immunised mice appears to be attributable to the CD4- 
cells, which produced the highest amounts of IL-10 (Fig. 9B). We also know from prior 
work in this lab, that splenic BCG counts were several logs lower than in the lungs. It is 
possible that suppressor T cells are present in the CD4- population of splenocytes. This 
could explain the very low levels of IL-2 in this cell fraction pre- and post- infection (Fig. 
10). CD8+ cells have been known to produce IL-10 in multiple sclerosis (Killestein, 
2003). Additionally, recent studies have demonstrated the presence of a CD8+CD25+ 
subset of cells in MHC class-II deficient mice exhibiting regulatory activity, as well as a 
phenotypically distinct subset of CD8+ cells secreting IL-10 that is a lineage of 
suppressor T cells (Bienvenu, 2005; Noble, 2006). Hence, it is possible that the high 
levels of IL-10 seen in the CD4- fraction of splenocytes were secreted by a subset of 
CD8+ suppressor cells. Such cells warrant further characterisation in my future work. 
 
IL-10 has been shown to reduce presentation of mycobacterial antigens to CD4+ T cells 
by inhibiting cathepsin-S dependent processing of MHC class II invariant chain in human 
macrophages infected with BCG (Sendide, 2005). This suggests that IL-10 induction is 
an immune evasion strategy of mycobacteria to enable their persistence in the host. It is 
therefore also possible that the IL-10 levels observed in the culture supernatants (Fig. 9) 
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 were attributable to BCG-infected macrophages. However, given that IL-10 was more 
significantly expressed in splenocyte fractions of sensitised mice that had significant 
cytotoxic activity than in control mice, this explanation is less likely. Instead, it is more 
possible that Tregs secreting IL-10 were down-regulating the murine inflammatory 
responses to BCG, similar to the requirement for IL-10 in suppressing excessive 
intestinal inflammation observed in IL-10 deficient mice (Kuhn, 1993; Berg, 1996). 
Hence, whereas Tregs may have an important role in reducing the potentially immuno-
pathogenic inflammatory responses in TB disease, this mechanism may also likewise 
reduce the host’s immune cell recruitment and inflammatory responses which are crucial 
for the response to live BCG administered as a vaccine. To further confirm that Treg cells 
are responsible for the IL-10 production in our model system, Treg phenotyping (looking 
for FoxP3+ CD25+ CD127- cells) in the infected lung at both 1 week and 3 weeks 
following BCG infection will be done in future work. 
 
5.5 Role of IFN-γ in cytotoxic responses  
The CD4+ cells were the predominant population producing IFN-γ in the BCG-infected 
lung, and this was augmented by M. chelonae-sensitisation. This was in spite of the 
elevated expression of IL-10 in such mice. IFN-γ, a proinflammatory cytokine produced 
in T helper 1 (Th1) responses, activates macrophages by inducing phagosome maturation 
and upregulating their antimicrobial molecules, such as iNOS and reactive oxygen 
species, against intracellular Mtb. IFN-γ is also known to be involved in T cell cytolytic 
activity, and in some TB- as well as non-TB-related studies, and the extent of cytotoxicity 
is proportional to levels of IFN-γ production (Maraskovsky, 1989; Diamond and Gill 
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 2000; Pathan, 2000). However, with respect to our experimental system, total and CD4- 
splenocytes had less IFN-γ production but higher cytotoxic activity in sensitised mice 
(Figs. 7C, 11A). The only exception was the splenic CD4+ cell fraction, which showed 
more than 2-fold higher cytotoxic activity in M. chelonae- than PBS-immunised mice, 
correlating with the higher levels of IFN-γ produced by the former (Fig. 7C, 11A). At 1-
week post-BCG infection, splenocytes generally produced higher levels of IFN-γ in 
sensitised than control mice, with CD4+ cells secreting 4-fold higher IFN-γ than the other 
subsets of cells in immunised mice (Fig. 11B). However, cytotoxic activity of total and 
CD4+ cells was similar in immunised and control mice, while CD4- cells in sensitised 
mice showed 3-fold lower cytotoxicity than control mice (Fig. 7A). The above results 
suggest that in our experimental system, the cytotoxicity of sensitised mice against BCG-
infected cells may not be entirely linked to IFN-γ production levels.  
 
5.6 Effects of Env sensitisation on BCG-induced immunity 
Together with evidence from earlier work in this lab showing that lungs of M. chelonae-
sensitised mice had lower BCG counts than that of control mice 3 weeks post-BCG 
challenge, pre-sensitisation to Env, such as M. chelonae, induced better cytotoxicity and 
would seem protective if BCG infection were considered as a surrogate model for TB 
infection. This is consistent with the observation that priming with Env provides, to some 
extent, protective immunity to other mycobacteria (Brown, 1985).  
 
However, the dual effects of Env-sensitisation described in this study – induction of 
cytolytic T cells against BCG-infected macrophages and down-regulation of 
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 inflammatory responses to BCG – are not beneficial for the prospects of BCG as a 
vaccine. BCG works only as a live vaccine, and immune responses to Mtb wanes if BCG 
is no longer viable (Olsen, 2004). As such, the replication of BCG is essential for it to be 
effective as a vaccine. Immunity primed by Env sensitisation blocks BCG replication, 
thereby reducing its protective efficacy, so such priming is disadvantageous to BCG as a 
vaccine (Brandt, 2002).  Nonetheless, this effect may be species-specific. Demangel et al 
have shown that murine sensitisation with certain species of Env reduces BCG counts 
without diminishing protective efficacy against Mtb challenge (Demangel, 2005). 
 
The data presented show that M. chelonae could induce Treg cells, thereby reducing the 
extent of inflammation at the site of infection, and yet Env-sensitisation clearly also 
increases the cytolytic activity of T cells against infected macrophages. Whereas Env 
sensitisation has a negative influence on BCG vaccine, the direct effects of immunity 
conferred by such sensitisation may be helpful in the response to pathogenic TB 
infection. A good balance of regulatory and activated pathogen-specific cells in Env-
immunised mice, where inflammatory responses are not excessive, yet appropriate 
effector T cell responses are maintained, would be optimal. This could be the basis on 
which another well-studied Env species, M. vaccae, may work as a TB vaccine – it is 
currently undergoing clinical trials (Stanford and Stanford 1994; Corlan, 1997; Waddell, 
2000; Mwinga, 2002; Vuola, 2003). It is important to note, though, that pre-sensitisation 
to naturally acquired doses of Env are unlikely to protect fully against TB, since rural 
populations in many African countries have been shown to have high levels of exposure 
to Env but still have high TB incidence.  
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It has also been shown, in a small scale study, that when the BCG vaccine is given early 
at birth, before possible exposure to Env, the longevity of the recall response to BCG, and 
hence the BCG-attributable immunity, is still lower in Malawi, where Env exposure is 
high than in the UK where Env exposure is low (Ben-Smith, communicated in ‘TB 
Vaccines for the World 2006’ conference, Vienna). It is possible that Env exposure even 
after BCG vaccination may limit the memory response induced by BCG. We intend to 
model this in young mice and extend the present study to understand how M. chelonae 
priming affects post-BCG memory responses.  
 
Given our present understanding on the effects of Env priming, such effects would be 
likely to affect any vaccine approach that is based on live BCG.  This raises doubts of 
whether development of future vaccines against TB should revolve around live BCG as 
the mainstay with or without genetic modifications. Unfortunately, such is the approach 
of at least three new TB candidates on clinical trial now (Bosch 2004; Matee, 2007).  
This is of concern as populations in most high TB incidence areas also have high Env 
exposure. Perhaps emphasis in research for new TB vaccines should therefore be focused 
on vaccines that do not cross-react with Env antigens – candidates in this direction would 
include subunit vaccines based on TB-specific proteins such as ESAT-6, which are not 
found in BCG.  
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 5.7 Conclusion 
This study demonstrated that murine M. chelonae sensitisation induced an increase in 
cytotoxic responses against autologous BCG-infected macrophages, both pre- and post- 
BCG challenge. CD4+ T cells were the major T cell subset involved in cytotoxicity 
primed by M. chelonae against BCG and peforin played a role in this process. Upon M. 
chelonae- sensitisation and subsequent infection with BCG, there was a reduction in lung 
inflammatory responses, and increase in IL-10 production. Taken together with the 
phenotypic characterization of the cells involved by others in our lab, this suggests the 
induction of Tregs which diminish the recruitment of inflammatory cells to the site of live 
BCG vaccination. This is the first work that elucidates the actual immune mechanisms 
that govern the epidemiologically observed phenomenon of reduced BCG vaccine 
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Middlebrook 7H9 broth 
 
Distilled 7H9 broth 50% 20% OADC 
Volume 
water powder Glycerol Tween 80  
400 ml 356.4 ml 1.88 g 1.6 ml 2 ml 40 ml 
 
All ingredients, except OADC, were added and autoclaved at 121 °C for 15 min. OADC 
was added before use. 
 
Middlebrook 7H10 broth 
 
Distilled 7H9 broth 50% 20% OADC 
Volume 
water powder Glycerol Tween 80  
400 ml 353.6 ml 7.6 g 4 ml 2 ml 40 ml 
 
All ingredients, except OADC, were added and autoclaved at 121 °C for 15 min. The 
agar was left to cool to 55 °C before OADC was added. The liquefied agar was aliquoted 
into 60 mm petri dishes and allowed to set. 
 
 
Complete supplement for BCG infection (10X FAC) 
 
Distilled Ferric Ammonium Sodium 
Volume 
water Citrate (FAC) glutamine 
L-
asparagine 
50 ml 50 ml 25 mg 1 g 1g 
 
All ingredients were added at room temperature and mixed by stirring.  Medium was 
sterilised by filter through a 0.22 μm filter.  
 
 
Red blood cell lysis solution (0.17 M NH4Cl) 
 
Nanopure Ammonim chloride Volume 
water (NH4Cl) 
10 ml 10 ml 90 mg 
 
All ingredients were added at room temperature and mixed by stirring.  Adjust pH to 7.3 
and autoclave at 121 °C for 15 min. Solution was stored at 4 °C before use. 
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